A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Novo Nordisk A/S
Study ID
NCT07481630
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NNC0487-0111 — DRUG
    NNC0487-0111 dose level 1 and dose level 2 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
  • Placebo (matched to NNC0487-0111 ) — DRUG
    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Study Details

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Key Dates

Start date
Apr 13, 2026
Status verified
Jun 2026
Primary completion
Aug 14, 2028
Completion
Aug 14, 2028

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0487-0111 dose level 1
    Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
  • Experimental: NNC0487-0111 dose level 2
    Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
  • Placebo Comparator: Placebo
    Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

Primary Outcome Measure

Relative change in body weight [ Time Frame: From baseline (week 0) to (week 80) ]

Central Contacts

Locations (19)

FacilityCityStateZIPSite coordinators
Arizona Research Center, Inc.PhoenixArizona85053-
Diablo Clinical Research, Inc.Walnut CreekCalifornia94598-
Chase Medical Research LLCHamdenConnecticut06517-
Chase Medical Research LLCWaterburyConnecticut06708-
Zenith clinical researchHollywoodFlorida33021-
CNS HealthcareJacksonvilleFlorida32256-
Angels Clinical Research InstituteMiami LakesFlorida33016-
Hope Clin Res & WellnessConyersGeorgia30094-
CenExel iResearch, LLCDecaturGeorgia30030-
Elite Clinical TrialsBlackfootIdaho83221-
MedVadis Research WatertownWalthamMassachusetts02451-
Jubilee Clinical Research, Inc.Las VegasNevada89106-
Great Lakes Medical ResearchWestfieldNew York14787-
Accellacare and KDCILM, LLCWilmingtonNorth Carolina28401-
Coastal Carolina Res CtrNorth CharlestonSouth Carolina29405-
VIP Trials_San AntonioSan AntonioTexas78230-
Charlottesville Med ResearchCharlottesvilleVirginia22911-
Health Res of Hampton RoadsNewport NewsVirginia23606-
Northwest Clinical Research CenterBellevueWashington98007-

Find similar trials in Phoenix, AZ

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Arizona Research Center, Inc.· Phoenix, AZDiablo Clinical Research, Inc.· Walnut Creek, CAChase Medical Research LLC· Hamden, CTChase Medical Research LLC· Waterbury, CTZenith clinical research· Hollywood, FLCNS Healthcare· Jacksonville, FL

Related Studies